Has Anju Pabby, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,779 in general payments to Anju Pabby, MD across 119 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Anju Pabby, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Anju Pabby, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Anju Pabby, MD

Dermatology · Washington, DCNPI 1992741011

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 119 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Revance Therapeutics, Inc. at 38.4% of the total. 2025 is the largest year on record at $1,435, 5.2 times the $276 reported in 2022. That places this record below the midpoint for dermatology clinicians in DC, where the typical reported total is $3,159.

$3,779in general payments, 2019–2025

Across 119 payments — averaging $31.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Revance Therapeutics, Inc.$1K
AbbVie$785
Incyte Corporation$335
Merz North America, Inc.$334
Galderma Laboratories, L.p.$256
Pfizer$115
plus $503 from 9 others

What the payments were for

Food & beverage$3,764100%
Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Revance Therapeutics, Inc.	50	$1,451
AbbVie(2 entities)	16	$785
Incyte Corporation	15	$335
Merz North America, Inc.	5	$334
Galderma Laboratories, L.p.	10	$256
Pfizer	5	$115
Sun Pharmaceutical Industries Inc.	4	$111
Strata Skin Sciences, Inc.	1	$90
Regeneron Healthcare Solutions, Inc.	3	$72
Solta Medical, A Division Of Bausch Health US, LLC	3	$70
Novartis	2	$51
Boehringer Ingelheim	1	$33
Botanix SB Inc	2	$31
Arcutis Biotherapeutics, Inc.	1	$23
Kyowa Kirin, Inc.	1	$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

DAXXIFY$609
BOTOX$375
KYBELLA$144
NEMLUVIO$128

How this compares

$3,779 in reported general payments places this provider in the 50th percentile of 73 dermatology providers in District of Columbia.

See all dermatology providers in District of Columbia →

Medicare billing

Part B allowed, 2024

$254,334

Medicare patients

590

Services billed

3,430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Fluocinonide	53	$2,992
Ketoconazole	131	$2,144
Desonide	38	$1,633
Clobetasol Propionate	11	$1,203
CiclopiroxCiclopirox Olamine	36	$1,056
Metronidazole	12	$869
Fluocinolone Acetonide	19	$859
Clindamycin Phosphate	26	$612
Minoxidil	40	$373
Mupirocin	30	$297
Triamcinolone Acetonide	54	$287
Doxycycline Hyclate	12	$182

Paid to pharmacies, not to this prescriber.

Other dermatology in Washington

Jonathan SilverbergWashington$4.5M
Adam FriedmanWashington$2.2M
Terrence KeaneyWashington$1.1M
Candrice HeathWashington$168K
Agnes ChangWashington$109K
Todd PerkinsWashington$102K
Karl SaardiWashington$101K
Noelle SherberWashington$96K
Yolanda HolmesWashington$80K
Cheri FreyWashington$79K

See the full list for District of Columbia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →